3Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol, 2002,83: 1267-1280.
4Lok ASF, McMahon BJ. AASLD practice guidline: Chronic hepatitis B : Update of recommendations. Hepatology, 2004,39: 857-861.
5Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine t reatment of chronic hepatits B. Hepatology, 2003, 37:748-755.
6Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post2t reatment durability of lamivudine induced HBeAg seroconversion. J Viral Hepat, 2002, 9:208-212.
7van Numen AB, Hansen BE, Sub DJ, et al. Durability of HBeAg seroeonversion following antiviral t herapy for chronic hepatitis B: relation to type of t herapy and pret reatment serum hepatitis B virus DNA and alanine aminot ransferase. Gut,2003,52:420-424.
8Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepat, 1996, 2: 1-35.
9Lai Cl, Ching CK, Tung AKM, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo controlled trial Hepatitis, 1997, 25 : 241.
10Summers J, Smith PM, Huang M, et al. Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus. Virology, 1991,65:1310-1317.
6STAMPLER MJ,KRAUSS RM,MA J,ei al. A prospective study oftriglyceride level,low- densitylipopmtein particle diameter,and riskof myocardial inlfarction[ J]. JAMA,2006,276( 11) :882.
7LAMLBER C,MANN S,PRANGE R. Assessment of deteminantsaffecting the dual topology of hepadnaviral large envelope proteins[J]. J Gener Vimlo,2010,85(5) :1221.
8BRUSS V. Envelopment of the hepatitis B virus nucleocapsid[ J ].Virus Research,2004,106(2) :199.
9CHAI N, GUDIMA S, CHANG J,et al. Immunondhesins containingpre-S domains of hepatitis B virus large envelope protein are secretedand inhibit virus infdction [J]. J Viral,2007 ,81 ( 10) :4912.
